HR
SAGE

Howe & Rusling’s Sage Therapeutics SAGE Stock Holding History

Howe & Rusling’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26
Closed -$1K – 1145
2022
Q1 		$1K Hold
26
– – ﹤0.01% 952
2021
Q4 		$1K Buy
+26
New +$1.09K ﹤0.01% 952
2020
Q4 		– Sell
-31
Closed -$2K – 990
2020
Q3 		$2K Hold
31
– – ﹤0.01% 733
2020
Q2 		$1K Buy
+31
New +$1.13K ﹤0.01% 764
2019
Q1 		– Sell
-78
Closed -$7K – 873
2018
Q4 		$7K Hold
78
– – ﹤0.01% 493
2018
Q3 		$11K Buy
+78
New +$12K ﹤0.01% 490

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Howe & Rusling's SAGE Position: Q2 2022 in Review

Howe & Rusling sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 26 shares — an estimated $1K sold.

Howe & Rusling first reported a position in SAGE in Q3 2018 and held it in 6 quarters. The position peaked at $11K in Q3 2018. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Howe & Rusling reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Howe & Rusling sold 26 Sage Therapeutics shares in Q2 2022, an estimated $1K.
  • Howe & Rusling first reported a position in Sage Therapeutics in Q3 2018 and held it in 6 quarters.
  • Howe & Rusling's Sage Therapeutics position peaked at $11K in Q3 2018.
  • 209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.